| Literature DB >> 24058651 |
Liang Gong1, Wei Zhang, Jianding Zhou, Jie Lu, Hua Xiong, Xueli Shi, Jianqiang Chen.
Abstract
BACKGROUND: Tumor hypoxia plays a fundamental role in resistance to therapy and disease progression. A number of studies have assessed the prognostic role of HIFs expression in head and neck cancer (HNC), but no consistent outcomes are reported.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24058651 PMCID: PMC3772872 DOI: 10.1371/journal.pone.0075094
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Flow diagram of study selection procedure.
Figure 2Forrest plot of Hazard ratio for the association of different HIF isoforms expression with overall survival.
Figure 3Forrest plot of Hazard ratio for the association of overexpressed Hif-1α with different disease subtype.
Figure 4Forrest plot of Hazard ratio for the association of overexpressed Hif-1α with different geographical locations.
Stratified analysis of pooled hazard ratios for head and neck cancer with overexpressed Hif-1α and Hif-2α.
| Hif-1α | Hif-2α | ||||||||||||
| Heterogeneity | Heterogeneity | ||||||||||||
| Number of studies | Number of patients | Pooled HR(95% CI) | P value | I2(%) | P value | Number of studies | Number of patients | Pooled HR(95% CI) | P value | I2(%) | P value | ||
| Disease subtype | |||||||||||||
| Head and neck (total) | 26 | 2293 | 1.71(1.34.-2.2) | 0 | 70.90% | 0 | 7 | 710 | 1,79(1.42–2.27) | 0 | 0% | 0.519 | |
| Nasopharynx | 5 | 445 | 2.07(1.23–3.49) | 0.006 | 22.50% | 0.271 | – | – | – | – | – | – | |
| Laryngeal | 5 | 458 | 1.38(0.87–2.19) | 0.168 | 62.50% | 0.031 | – | – | – | – | – | – | |
| Oropharynx | 2 | 331 | 1.76(1.05–2.97) | 0.033 | 61% | 0.109 | – | – | – | – | – | – | |
| Oral | 9 | 650 | 2.1(1.11–3.97) | 0.023 | 81.70% | 0 | 3 | 207 | 1.5(1.02–2.2) | 0.038 | 0% | 0.437 | |
| Study location | |||||||||||||
| Europe and Australia | 10 | 1013 | 1.13(0.77–1.66) | 0.521 | 78.30% | 0 | 4 | 503 | 2(1.48–2.68) | 0 | 0% | 0.529 | |
| Asia | 16 | 1280 | 2.34(1.76–3.1) | 0 | 48.90% | 0.015 | 3 | 207 | 1.5(1.02–2.2) | 0.038 | 0% | 0.437 | |
| Definition of positive | |||||||||||||
| Staining | 4 | 345 | 1.98(0.85–4.58) | 0.112 | 80.80% | 0.001 | – | – | – | – | – | – | |
| Percentage | 12 | 1034 | 1.46(0.93–2.28) | 0.098 | 76.80% | 0 | 2 | 100 | 2.44(1–5.92) | 0.049 | 0% | 0.531 | |
| Staining and percentage | 8 | 1108 | 1.82(1.42–2.33) | 0 | 9.90% | 0.353 | 4 | 513 | 1.89(1.44–2.48) | 0 | 0% | 0.412 | |
| Disease Stage | |||||||||||||
| I-IV | 10 | 879 | 1.59(0.96–2.62) | 0.069 | 81.40% | 0 | 2 | 118 | 1.49(0.91–2.46) | 0.115 | 39.50% | 0.198 | |
| II-IV | 3 | 183 | 2.07(1.19–3.59) | 0.01 | 0% | 0.455 | – | – | – | – | – | – | |
| III-IV | 2 | 235 | 1.32(1.02–1.72) | 0.037 | 0% | 0.93 | – | – | – | – | – | – | |
| Variate analysis | |||||||||||||
| Multivariate | 15 | 1378 | 1.68(1.21–2.32) | 0.002 | 73.70% | 0 | 2 | 349 | 1.8(1.25–2.6) | 0.002 | 14.20% | 0.28 | |
| Univariate | 11 | 915 | 1.78(1.17–2.7) | 0.007 | 69.10% | 0 | 5 | 361 | 1.79(1.32–2.43) | 0 | 0.70% | 0.402 | |
| Positive site | |||||||||||||
| Nuclear | 16 | 1499 | 1.52(1.03–2.25) | 0.037 | 77.50% | 0 | 3 | 327 | 1.37(0.93–2.03) | 0.115 | 0% | 0.859 | |
| Nuclear/cytoplasm | 8 | 654 | 1.98(1.44–2.74) | 0 | 46.90% | 0.068 | 3 | 362 | 2.04(1.51–2.75) | 0 | 0% | 0.457 | |
| Quality score | |||||||||||||
| ≥6 | 18 | 1614 | 1.97(1.49–2.61) | 0 | 66.50% | 0 | 4 | 340 | 1.73(1.27–2.36) | 0.001 | 4.40% | 0.371 | |
| <6 | 8 | 679 | 1.22(0.74–2.03) | 0.432 | 74.30% | 0 | 3 | 370 | 1.88(1.32–2.68) | 0 | 0% | 0.379 | |